Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

January 02, 2020

Taking Ticagrelor? Frank, Proactive Patient Conversations are Needed to Help With Adherence

News Daily News

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

Yael L. Maxwell

May 17, 2019

News Conference News TCT 2018

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

Shelley Wood

September 26, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

News Daily News

Subanálisis del PLATO: El Ticagrelor es Rentable en Pacientes con SCA

June 26, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

Advertisement

What’s Going to Be Hot at TCT 2025

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Subanálisis del PLATO: El Ticagrelor es Rentable en Pacientes con SCA

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content